BTCure is a pan-European research initiative involving 24 academic and 14 industrial partners. The program is funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and has a total budget of approximately 35 million Euros.
The aim of this initiative is to bring together academic rheumatology research and research in pharmaceutical companies in Europe to further broaden our knowledge of disease causing factors and disease progression in Rheumatoid Arthritis (RA), thereby identifying improved or targeted therapeutic treatments. The focus of BTCure will be the development of new diagnostic methods to discover the early forms of RA as well as tools to separate the different forms of RA, where different molecular mechanisms are involved and where different therapies may be required.
The strategy of BTCure is to achieve this goal by using a transnational, collaborative approach and by driving this ambitious project forward in a joint effort. Thus, BTCure is the largest European program so far, aimed at developing new therapies against Rheumatoid Arthritis (RA).
The different tasks of BTCure have been grouped into 10 different work-packages, which are shortly summarized under the work package descriptions to the left.